Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838782 | 1.00 | KMT2A (0.41) | KMT2AEPHX1EPHX2SPHK1FUCA1 | |
| SCHEMBL595423 | 0.90 | MEN1 (0.39) | KMT2AEPHX1EPHX2MMP2 | |
| SCHEMBL10001421 | 0.90 | MEN1 (0.39) | KMT2AEPHX1EPHX2MMP2 | |
| SCHEMBL17838788 | 0.80 | KMT2A (0.37) | KMT2AEPHX1EPHX2SPHK1FUCA1 | |
| SCHEMBL16408935 | 0.78 | EPHX2 (0.41) | KMT2AEPHX2 | |
| SCHEMBL21941459 | 0.73 | SPHK1 (0.54) | EPHX1SPHK1 | |
| SCHEMBL8269540 | 0.72 | TRPV1 (0.41) | KMT2AEPHX2 | |
| SCHEMBL16408932 | 0.72 | THRB (0.34) | — | |
| SCHEMBL26017783 | 0.72 | SPHK1 (0.57) | EPHX1SPHK1 | |
| SCHEMBL17702625 | 0.69 | KMT2A (0.70) | KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369133-B2 | Immunosuppressive compounds and therapeutics | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160175281-A1 | IMMUNOSUPPRESSIVE COMPOUNDS AND THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369133-B2 | Immunosuppressive compounds and therapeutics | NFATC1, ICOS, TSLP | KMT2A 2758/4885EPHX1 1261/4885EPHX2 2887/4885 |
| US-20160175281-A1 | IMMUNOSUPPRESSIVE COMPOUNDS AND THERAPEUTICS | NFATC1, ICOS, TSLP | KMT2A 2758/4885EPHX1 1261/4885EPHX2 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.